Achieving and sustaining remission in bipolar i disorder with ziprasidone: A post hoc analysis of a 24-week, double-blind, placebo-controlled study

Clinical Drug Investigation

Volumn 32, Issue 11, 2012, Pages 747-754

  Pae, Chi Un ^a,b   Masand, Prakash S ^c   Mandel, Francine S ^d   O'Gorman, Cedric ^d  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Global Medical Education Inc   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; LITHIUM; LORAZEPAM; PLACEBO; VALPROIC ACID; ZIPRASIDONE; ZOLPIDEM;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR I DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MANIA RATING SCALE; MENTAL PATIENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84873434578     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-012-0009-1     Document Type: Article

References (24)

1. Hirschfeld RM, Calabrese JR, Frye MA, et al. Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening. Psychopharmacol Bull. 2007;40(3):7-14.
2. Martinez-Aran A, Vieta E, Chengappa KN, et al. Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. Bipolar Disord. 2008;10(5):566-79.
3. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 Suppl):1-50.
4. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
6. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-35.
7. Miller DS, Yatham LN, Lam RW. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. J Clin Psychiatry. 2001;62(12):975-80.
8. Berk M, Ng F, Wang WV, et al. The empirical redefinition of the psychometric criteria for remission in bipolar disorder. J Affect Disord. 2008;106(1-2):153-8.
9. Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11(5):453-73.
10. Riedel M, Moller HJ, Obermeier M, et al. Response and remission criteria in major depression: a validation of current practice. J Psychiatr Res. 2010;44(15):1063-8.
11. Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry. 2010;71(2):130-7.
12. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159-71.
13. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2004.
14. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163(2):217-24.
15. Chengappa KN, Baker RW, Shao L, et al. Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord. 2003;5(1):1-5.
16. Gopal S, Steffens DC, Kramer ML, et al. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry. 2005;66(8):1016-20.
17. Ketter TA, Agid O, Kapur S, et al. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. J Psychiatr Res. 2010;44(1):8-14.
18. Ketter TA, Jones M, Paulsson B. Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania. J Affect Disord. 2007;100(Suppl. 1):S45-53.
19. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry. 2000;57(9):841-9.
20. Masand PS, Eudicone J, Pikalov A, et al. Criteria for defining symptomatic and sustained remission in bipolar I disorder: a post hoc analysis of a 26-week aripiprazole study (study CN138-010). Psychopharmacol Bull. 2008;41(2):12-23.
21. Masand P, O'Gorman C, Mandel FS. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data. Schizophr Res. 2011;126(1-3):174- 83.
22. Rosa AR, Sanchez-Moreno J, Martinez-Aran A, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5.
23. Chengappa KN, Hennen J, Baldessarini RJ, et al. Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disord. 2005;7(1):68-76.
24. Gitlin MJ, Abulseoud O, Frye MA. Improving the design of maintenance studies for bipolar disorder. Curr Med Res Opin. 2010;26(8):1835-42.